HYFTOR™ (sirolimus topical gel) 0.2% is now commercially available in the U.S. by prescription as the first topical treatment indicated for facial angiofibroma associated with tuberous sclerosis complex in adults and children 6 years of age or older.
FDA-approved, cGMP-manufactured HYFTOR™ is available through specialty pharmacies equipped to handle cold storage requirements and meet the unique needs of the small population of tuberous sclerosis complex (TSC) patients with facial angiofibroma and their providers.
At Nobelpharma America, we recognize no two patients are the same and strive to provide support and assistance to eligible patients in need. The Nobelpharma Connect portal offers a range of resources and services to help individuals with access and information throughout the treatment journey.
Nobelpharma Connect includes personalized services and ongoing support across the following areas:
Contact Nobelpharma Connect Monday through Friday, from 8 a.m. – 6 p.m. ET.
PHONE: 1-877-649-3867 | FAX: 1-877-240-3022 | WEBSITE: nobelpharmaconnect.com
HYFTOR is an mTOR inhibitor immunosuppressant indicated for the treatment of facial angiofibroma associated with tuberous sclerosis in adults and pediatric patients 6 years of age and older.
HYFTOR is contraindicated in patients with a history of hypersensitivity to sirolimus or any other component of HYFTOR.
WARNINGS AND PRECAUTIONS
The most common adverse reactions (≥1%) are dry skin, application site irritation, pruritus, acne, acneiform dermatitis, ocular hyperemia, skin hemorrhage, and skin irritation.
USE IN SPECIFIC POPULATIONS
Please see full Prescribing Information for additional safety information.